ArticleTranslational cancer research2020
The effects of CYP24A1 on clinicopathological features and the prognosis of pancreatic ductal adenocarcinoma.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Vitamin D and Pancreatic Ductal Adenocarcinoma-A Review of a Complicated Relationship.Nutrients · 2024Pooled it
- Expression of vitamin D receptor, CYP24A1, and CYP27B1 in normal and inflamed canine pancreases.Frontiers in veterinary science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a type of exocrine pancreatic cancer that presents itself in the form of a highly malignant tumor. However, in the past few decades, with breakthroughs in the diagnosis and treatment of malignant tumors, there have yet to be satisfactory results for the diagnosis (early diagnosis) and treatment of PDAC. Therefore, the biological behavior of PDAC still requires more research to be understood. CYP24A1 is currently considered to be an essential part of vitamin D (VD) metabolism and increasingly reported to be associated with malignant tumors. Therefore, this study aims to explore the relationship between CYP24A1 and the clinicopathological features and prognosis of PDAC.
methodsSeventy-three surgical PDAC cases were collected and follow-ups were made. The expression of CYP24A1 was obtained by the immunohistochemistry and the tissue FAXS cytometry (TFC) system. The related quantitative indices included the percentage of positive cells (%) and the average staining intensity of the positive cells (in) in the cancer zone (C) and the adjacent non-cancer zone (ANC). The relationship between CYP24A1 and the clinicopathological parameters, as well as the prognosis of PDAC was then analyzed. Furthermore, Fluorescence quantitative PCR, Western-blot, siRNA, and phenotypic testing were implemented in the Pan-C1 PDAC cells.
resultsIn normal pancreatic tissue, CYP24A1 was approximately "zero-expressed" in the exocrine glands. In the C and ANC zones, the expression of CYP24A1 increased significantly. In cases with a higher C%, the proportion of lymph node metastasis was lower (P=0.071); In cases with a higher ANC% (P=0.026) and higher ANCin (P=0.079), the proportion of high differentiation was higher; in survival analysis, C%, Cin had a significant effect on survival and those with higher parameters had a lower risk of death. In the cell experiments, after CYP24A1 was silenced, the migration ability of PDAC cells did not change significantly and its proliferation (P=0.034) and invasion (P=0.002) ability decreased significantly.
conclusionsCYP24A1 has a significant effect on the development and prognosis of PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.